To the Editor:Male androgenic alopecia(MAA)is the most common hair loss disorder characterized by miniaturization of hair follicles and progressive hair loss.[1]Although oral drugs,topical agents,and laser therapy can...To the Editor:Male androgenic alopecia(MAA)is the most common hair loss disorder characterized by miniaturization of hair follicles and progressive hair loss.[1]Although oral drugs,topical agents,and laser therapy can promote hair growth,minoxidil is the only topical therapy approved by the United States Food and Drug Administration.Fibroblast growth factors(FGFs)have a wide range of biological functions.The basic FGF(bFGF)promotes the growth of the hair follicle in mice,indicating its potential as a therapeutic agent for MAA.[2]The nano-microneedle is a new device that can promote transdermal absorption of topical drugs,[3]and increase drug penetration by up to 10 or 20 times.In this study,we compared the safety and efficacy of topical minoxidil,nano-microneedle-assisted FGF,and a combination of the two.展开更多
基金supported by grants from the National Key Research and Development Program of China(No.2016YFC0901504)the 111 Project(No.D18011).
文摘To the Editor:Male androgenic alopecia(MAA)is the most common hair loss disorder characterized by miniaturization of hair follicles and progressive hair loss.[1]Although oral drugs,topical agents,and laser therapy can promote hair growth,minoxidil is the only topical therapy approved by the United States Food and Drug Administration.Fibroblast growth factors(FGFs)have a wide range of biological functions.The basic FGF(bFGF)promotes the growth of the hair follicle in mice,indicating its potential as a therapeutic agent for MAA.[2]The nano-microneedle is a new device that can promote transdermal absorption of topical drugs,[3]and increase drug penetration by up to 10 or 20 times.In this study,we compared the safety and efficacy of topical minoxidil,nano-microneedle-assisted FGF,and a combination of the two.
